The TPP and the Regulation of Medicines in Canada
From: The Trans-Pacific Partnership and Canada
explore the implications of the TPP for drug costs resulting from the agreement’s provisions on intellectual property, services and investment.
JOEL LEXCHIN received his MD from the University of Toronto in 1977. He is an emeritus professor in the School of Health Policy and Management at York University in Toronto where he taught health policy. He has worked for twenty-eight years in the emergency department of Toronto's University Health Network and is the author or co-author of over 150 peer-reviewed articles on a wide variety of topics concerned with Canadian and international pharmaceutical policy. His book Private Profit versus Public Policy: The Pharmaceutical Industry and the Canadian State was published by University of Toronto Press at the end of October 2016.